La cadena de opciones muestra datos clave de las opciones de acciones de HOOKIPA Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para HOOKIPA Pharma..

HOOKIPA Pharma (NASDAQ:HOOK) Bolsa, Cadena de Opciones

HOOKIPA Pharma

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.

HOOKIPA Pharma Inc

Hooker Furnishings Corporation - Common Stock

Hooker Furnishings Corp

Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the industry-leading software and consulting service expertise to successfully implement the FDA roadmap.

Government

News

Regulations

Simulations Plus Supports FDA's Plan to Reduce Animal Testing with New Approach Methodologies

Piper Sandler analyst Scott Siefers maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Neutral and lowers the price target from $45 to $41.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Truist Finl, Lowers Price Target to $41

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has kicked off the week with a 4% gain, following the strong start of other major cryptocurrencies.
Traders and analysts say the recent sideways action could soon give way to a <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">significant bullish breakout</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.12</td>
<td>$123.9 billion</td>
<td>+3.7%&nbsp;</td>
<td>&nbsp;-1.5%</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$86,903.25</td>
<td>$1.72 trillion</td>
<td>+3.3%&nbsp;</td>
<td>+2.5%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$1,625.29</td>
<td>$196.3 billion</td>
<td>+3.2%&nbsp;</td>
<td>-3.5%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto chart analyst Ali Martinez flagged a volatility squeeze on XRP's 4-hour Bollinger Bands, indicating that a major price move is imminent.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Bollinger Bands are squeezing on the <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> 4-hour chart, signaling that a major price move could be just around the corner. <a href="https://t.co/Yeu0f71PPG">pic.twitter.com/Yeu0f71PPG</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1914079963193487512?ref_src=twsrc%5Etfw">April 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Pseudonymous trader Captain Faibik <a href="https://x.com/CryptoFaibik/status/1914219952027877763">echoed</a> the sentiment, suggesting now is the time to accumulate XRP ahead of what he expects to be an "explosive" rally. His midterm price target is at $5.
Pseudonymous trader Dark Defender <a href="https://x.com/DefendDark/status/1914214815188340855">pointed to</a> XRP nearing the end of its consolidation phase, with momentum building inside a tightening range. 
Defender sees XRP's bullish structure is intact as the overall crypto markets are charged up as never before. He marks key resistance levels to watch: $2.222 and $2.75. The support levels are $1.88 and $1.60.
Statistics: According to Coinglass, XRP open interest has climbed by 3.9% to $3.3 billion, while derivatives volume spiked 57.3% in the past 24 hours — a strong signal of renewed trader engagement.
Liquidations over the same period hit $4.12 million, with $2.7 million in short liquidations, suggesting some traders may be bracing for an unexpected breakout.
Community News: On April 18, HashKey Capital <a href="https://x.com/HashKey_Capital/status/1913088161229795328">announced</a> Asia's first XRP Tracker Fund, with Ripple stepping in as the anchor investor. 
The move marks a new phase of institutional adoption for XRP, expanding regulated access to the token.
Following similar funds for Bitcoin and Ethereum, this is HashKey's third tracker product, designed to give professional investors exposure without the challenges of custody or direct trading.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44888065/xrps-correction-explained-key-levels-sentiment-shifts-and-whats-next">XRP&#8217;s Correction Explained: Key Levels, Sentiment Shifts, and What&#8217;s Next</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Jumps 4%: What Is Going On?

Seaport Global analyst Michael Harrison upgrades Innospec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOSP#NASDAQ">IOSP</a>) from Neutral to Buy and announces $155 price target.

Upgrades

IOSP

Seaport Global Upgrades Innospec to Buy, Announces $155 Price Target

WIIM

Capital One and Discover shares are trading higher after the Board of Governors of the Federal Reserve System and the Office of the Comptroller of the Currency approved their proposed merger.

TSLA: -4% &#x7C; <a href="https://www.benzinga.com//node/44893694">Tesla shares are trading lower following a report indicating the company postponed the US debut of an affordable version of its Model Y SUV.</a>
&nbsp;
NFLX: 5% &#x7C; <a href="https://www.benzinga.com//node/44893675">Netflix shares are trading higher after the company on Thursday reported a Q1 earnings beat and issued strong Q2 guidance.</a>
&nbsp;
IVVD: 22% &#x7C; <a href="https://www.benzinga.com//node/44893948">Invivyd shares are trading higher after the company signed a $30 million term loan facility with Silicon Valley Bank.</a>

Movers

Trading Ideas

IVVD

NFLX

TSLA

Market-Moving News for April 21st

A growing number of cryptocurrency companies are preparing to enter the U.S. banking system, propelled by a policy shift under President Donald Trump aimed at <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42644568/institutional-crypto-adoption-for-real-this-time-says-messari">integrating digital assets into mainstream finance</a>.
What Happened: Firms like Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) and BitGo are planning to apply for bank charters, The Wall Street Journal <a href="https://www.wsj.com/finance/currencies/crypto-knocks-on-the-door-of-a-banking-world-that-shut-it-out-082b3968">reported</a>, quoting sources.
Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Paxos are also exploring regulatory approvals to operate with similar authority. 
These developments follow the Trump administration's commitment to establishing the U.S. as a global leader in digital assets, including through new legislation targeting stablecoin oversight.
Recent bills moving through Congress propose a <a href="https://www.benzinga.com/content/44516699/u-s-congress-advances-stablecoin-regulation-with-the-introduction-of-the-stable-act">regulatory framework for stablecoins</a>, mandating that issuers secure banking licenses or charters.
These digital tokens, typically pegged to fiat currencies, are used as a bridge between volatile cryptocurrencies and traditional money.
Some crypto firms are aiming for national trust bank or industrial bank charters that are essentially licenses that would allow them to hold customer deposits or issue loans. 
Others are seeking limited permissions specifically for issuing stablecoins.
BitGo, a crypto custody firm and reserve manager for the Trump family's stablecoin project USD1, is nearing the submission of its bank charter application, according to individuals familiar with its plans.
Anchorage Digital, currently the only federally chartered crypto bank in the U.S., has invested tens of millions of dollars to meet regulatory standards. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44867243/binance-advising-nations-on-strategic-bitcoin-reserves-crypto-regulation-report">Binance Advising Nations On Strategic Bitcoin Reserves, Crypto Regulation: Report</a>
CEO Nathan McCauley acknowledged the operational challenges, saying, "It has not been easy," but emphasized the importance of intertwining full regulatory compliance with the crypto sector.
Anchorage recently became a custodian for BlackRock's iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) and partnered with Cantor Fitzgerald and Copper on a $2 billion bitcoin-backed lending initiative. 
Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>), the world's largest stablecoin by market cap at $145 billion, is a major Cantor client.
This integration marks a reversal from two years ago when the collapses of crypto firms and banks like Silvergate and Signature led to a regulatory clampdown, forcing traditional financial institutions to distance themselves from the crypto sector.
Why It Matters: Trump's return to office has changed the tone.
Regulations that once required banks to seek explicit approval before offering crypto services have been softened, and new federal guidance on bank-crypto relationships is expected later this year.
Legacy financial institutions are adjusting course. 
Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) CEO Brian Moynihan said in February the bank is prepared to issue a stablecoin once legal clarity is established. 
U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) has also resumed crypto custody services via a partnership with NYDIG.
International banks are taking note. 
A consortium including Deutsche Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) and Standard Chartered (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SCBFF#OTC">SCBFF</a>) is exploring expansion into the U.S. crypto market. Deutsche Bank declined to comment, and Standard Chartered did not respond.
However, caution persists in some corners. 
KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) CEO Chris Gorman noted potential competitive threats from crypto and cited regulatory concerns, particularly around transparency and anti-money laundering enforcement. "It's hard to trace," he said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44861571/donald-trump-blasts-too-late-and-wrong-fed-chair-powell-but-polymarket-traders-doubt-his-termination-will-come-fast-enough">Donald Trump Blasts &#8216;Too Late And Wrong&#8217; Fed Chair Powell, But Polymarket Traders Doubt His &#8216;Termination&#8217; Will Come &#8216;Fast Enough&#8217;</a></li>
</ul>
Image: Shutterstock

$USDC

$USDT

COIN

IBIT

SCBFF

Deutsche Bank, Standard Chartered Reportedly Looking Into Expanding To US Crypto Market

Needham analyst Chris Pierce reiterates Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and maintains $13 price target.

Reiteration

ACHR

Needham Reiterates Buy on Archer Aviation, Maintains $13 Price Target

Piper Sandler analyst Andrew Liesch maintains Westamerica Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WABC#NASDAQ">WABC</a>) with a Neutral and lowers the price target from $54 to $50.

WABC

Piper Sandler Maintains Neutral on Westamerica Bancorp, Lowers Price Target to $50

Barrington Research analyst Gary Prestopino maintains LKQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) with a Outperform and maintains $60 price target.

Barrington Research Maintains Outperform on LKQ, Maintains $60 Price Target

Barrington Research analyst Michael Petusky maintains Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) with a Outperform and maintains $38 price target.

OPCH

Barrington Research Maintains Outperform on Option Care Health, Maintains $38 Price Target

HemoSphere Alta&#x2122; Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical Situations
FRANKLIN LAKES, N.J., April 21, 2025 /PRNewswire/ --&nbsp;BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI) based algorithms that can help clinicians proactively address blood pressure instability and optimize blood flow to help avoid potential life-threatening situations during procedures.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
HemoSphere Alta&#x2122; platform is the company's most advanced hemodynamic monitoring technology available and is the first major product launch from the Advanced Patient Monitoring business since its acquisition by BD. The new product advances BD's leadership in smart, connected care technologies that use clinical data and AI to help clinicians improve patient outcomes and optimize clinical workflows.
 &nbsp;

BD Unveils HemoSphere Alta Advanced Monitoring Platform With Predictive, AI Based Algorithms

On April&nbsp;17, 2025, the U.S. Department of the Army announced through the publication of its Justification to Fair Opportunity ("JEFO") on SAM.gov that it will extend the current period of performance for the various task orders under the&nbsp;Logistics Civil Augmentation Program V indefinite delivery and indefinite quantity contract to support U.S. military operations worldwide ("LOGCAP V") with V2X,&nbsp;Inc. The Company is one of four award recipients of LOGCAP V and has several task orders, including the Kuwait Task Order,&nbsp;Iraq Task Order and INDOPACOM Task Order, among others, each of which is scheduled to extend through June&nbsp;2030.

V2X Inc. Secures Extended Military Support Contracts Under US Army's LOGCAP V Program

<a href="https://www.reuters.com/world/china/huawei-readies-new-ai-chip-mass-shipment-china-seeks-nvidia-alternatives-sources-2025-04-21/" title="https://www.reuters.com/world/china/huawei-readies-new-ai-chip-mass-shipment-china-seeks-nvidia-alternatives-sources-2025-04-21/">https://www.reuters.com/world/china/huawei-readies-new-ai-chip-mass-shipment-china-seeks-nvidia-alternatives-sources-2025-04-21/</a>

Tech

NVDA

Reuters Reported Earlier Huawei Preparing New AI Chip For Mass Shipment As Nvidia Alternative

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18040107/Chagee-news-wrap-0418-900x600-1.png" alt="" class="wp-image-11026" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18040107/Chagee-news-wrap-0418-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18040107/Chagee-news-wrap-0418-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18040107/Chagee-news-wrap-0418-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The listing was the first in the U.S. by a Chinese premium tea drink maker, which prides itself on the simplicity of its products and focus on the country's ancient tea culture
Premium tea drink maker&nbsp;Chagee Holdings Ltd.&nbsp;(CHA.US)&nbsp;<a href="https://www.globenewswire.com/news-release/2025/04/17/3063193/0/en/Chagee-Holdings-Limited-Announces-Pricing-of-Initial-Public-Offering.html">raised</a>&nbsp;$411 million (3 billion yuan) this week in the biggest IPO this year by a Chinese company, setting itself apart from a crowded group not only by being first to list in the U.S., but also with its traditional approach to one of China's most famous drinks.
The company raised the sum by selling 14.7 million American depositary shares (ADS) to investors for $28 each and could raise an additional $61.6 million if its underwriters exercise an overallotment option. That makes it the biggest U.S. IPO by a Chinese company since robotaxi operator Pony AI raised about $400 million in a Nasdaq IPO last November. Chagee's stock rose 15.9% on Thursday, its first trading day, valuing the company at $5.95 billion.
Founded in 2017 in Southwest China's Yunnan province, famous for its pu'er-style teas, Chagee has set itself apart from its peers with its simpler, more purist approach to China's tea culture that dates back thousands of years. The company likes to say that such culture is "in its bones," with most of its drinks consisting of milk and tea in various combinations.
That differs markedly from its rivals, many of those listed in Hong Kong, that add a wide range of ingredients to their products, from tapioca pearls, to cheese foam and fruit. The company also emphasizes traditional themes in its packaging and store decorations, including a logo inspired from Consort Yu, a famous figure in Peking Opera.
Chagee is also famous for its homier, more comfortable stores, with some likening that to the approach used by global coffee giant Starbucks. Unlike most of its rivals, whose shops often consist of little more than a window where customers can grab their order and go, Chagee's shops contain seating areas where people can consume their drinks, reminiscent of Starbucks' "third place" concept.
Also like Starbucks, the company prides itself on its treatment of employees, and invited some of those everyday workers, along with some of its franchisees, to ring the opening bell when its shares started trading on the Nasdaq.
Chagee is very much like its peers in reporting explosive growth over the last few years, riding a wave of popularity for their high-end tea drinks among China's growing urban class. Its store count jumped about sixfold from 1,087 shops in the fourth quarter of 2022 to 6,440 at the end of 2024, with franchisees accounting for 97% of those. The company's revenue has grown at a similar rate, rising to 12.4 billion yuan ($1.7 billion) last year from 492 million yuan in 2022.
The company recorded its first profit of 803 million yuan in 2023, and the figure more than tripled last year to 2.51 billion yuan.
In addition to its core China operation, Chagee also sees global expansion as a major new frontier going forward. The company disclosed in its prospectus that it is aiming to operate 1,000 to 1,500 global stores by the end of this year, and has also separately confirmed it plans to open its first U.S. store in Los Angeles later this year.

Asia

Equities

IPOs

Nasdaq IPO Positions Chagee For Global Expansion

Wells Fargo initiates coverage on Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Equal-Weight rating and announces Price Target of $17.

Initiation

STAA

Wells Fargo Initiates Coverage On Staar Surgical with Equal-Weight Rating, Announces Price Target of $17

Piper Sandler analyst Matt Farrell maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and raises the price target from $1100 to $1150.

Piper Sandler Maintains Overweight on Netflix, Raises Price Target to $1150

Money‑management guru Dave&nbsp;Ramsey is urging Americans to treat Social Security as a bonus, not a backbone, warning that the program's cash crunch could slice benefits within a decade.
What Happened: "Don't count on it. Or don't count on all of it," a Ramsey Solutions blog <a href="https://www.ramseysolutions.com/retirement/how-does-social-security-work#cookie-banner">post</a> says, bluntly rebranding the program as "Social Insecurity.
The alarm reflects the latest Social Security Trustees <a href="https://www.ssa.gov/oact/trsum/">report</a>, which projects the combined retirement and disability trust funds will run dry in 2035; ongoing payroll taxes would then cover only about 83 percent of promised checks. Demographic math compounds the squeeze: 2.7 workers now support each beneficiary, a ratio expected to fall to 2.4 by 2035 as baby boomers swell the over‑65 population from 61 million to 77 million.
Fear of a haircut is widespread. An AARP <a href="https://www.aarp.org/social-security/benefits-current-status-future-stability/">survey</a> found 75 percent of Americans 50 and older doubt the system will be there when they need it.
See also: <a href="https://www.benzinga.com/25/04/44829975/joe-biden-calls-social-security-a-sacred-promise-slams-trump-administrations-efforts-to-damage-the-program-theyre-shooting-first-and-aiming-later">Joe Biden Calls Social Security A &#8216;Sacred Promise,&#8217; Slams Trump Administration&#8217;s Efforts To Damage The Program: &#8216;They&#8217;re Shooting First And Aiming Later&#8217;</a>
Lawmakers have floated fixes ranging from higher payroll caps to later retirement ages, but Congress has failed to pass a solvency package since 1983. Ramsey's advice: assume reform stalls and build a private nest egg. "If by some miracle Social Security is around when you retire, you'll have some extra money to work with," he writes. "But understand, it's your job to take care of you and your family, not Uncle Sam's."
With trust‑fund depletion inching closer each spring, the personal‑finance host's blunt mantra lands as a rallying cry: plan for less, save for more, and treat any future check as gravy.
What To Know: Ramsey has previously warned that Social Security was never meant to fund a full retirement. The average 2025 benefit of&nbsp;$1,976 a month leaves most retirees short, so he <a href="https://www.benzinga.com/personal-finance/25/01/43064384/dave-ramseys-top-warnings-about-social-securitys-flaws-and-how-to-protect-your-financial-future">urges people</a> to become debt‑free, stock an emergency fund, and invest 15% of their income for the future.
He also flags the program's <a href="https://www.benzinga.com/24/12/42273289/suze-orman-slams-social-security-fearmongering-you-really-think-washington-is-going-to-do-nothing-and-cut-benefits-by-25-cmon">shaky outlook</a>: its trust funds could run dry by&nbsp;2035, cutting payments by roughly a quarter as the worker‑to‑beneficiary ratio shrinks. Ramsey tells clients to view Social Security as a bonus, <a href="https://www.benzinga.com/personal-finance/24/08/40374894/financial-guru-dave-ramsey-advises-take-social-security-at-62-but-this-essential-step-is-non-neg">claim at&nbsp;62</a> only if they invest the checks, and build wealth through disciplined saving rather than rely on Washington.
Read next: <a href="https://www.benzinga.com/personal-finance/25/04/44890948/she-collected-her-moms-social-security-for-25-years-now-shes-facing-justice">She Collected Her Mom&#8217;s Social Security For 25 Years — Now She&#8217;s Facing Justice</a>

Education

General

Dave Ramsey Tells Retirees 'Don't Count On it, Or Don't Count On All Of It' — Why He Doubts Social Security's Future

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board gave an oral presentation titled, "Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial" at the 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East.
The ‘9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East' was held April 18-20, 2025 in Abu Dhabi, United Arab Emirates (UAE). The meeting convened clinicians including neurologists, psychiatrists, and geriatricians, nurses, public health workers, researchers, social workers, students, caregivers, and community advocates from the Middle East and North Africa (termed the MENA region), USA, Europe and other countries with an interest in epidemiology, clinical/research, medicine, basic science, and healthcare advocacy related to Alzheimer's disease and related disorders (ADRD) in the region. Specifically, an emphasis on region specific healthcare delivery were addressed.

AVXL

Anavex Says Marwan Noel Sabbagh Presents Blarcamesine Phase IIb/III Findings At 9th International Conference On Alzheimer's Disease and Related Disorders in Middle East

Chinese battery manufacturer CATL (Contemporary Amperex Technology Co. Limited) has launched the second-generation ‘Shenxing' fast-charging battery.
What Happened: The company announced the second-generation battery at an event in Shanghai, reported Reuters on Monday. Shenxing batteries would power over 67 new EVs this year, CATL's Chief Technology Officer, Gao Huan, said.
The new battery would enable a range of 520 km or approximately 323 miles on a 5-minute charge. The battery can also be charged from 0% to 80% in 15 minutes in cold weather.
The report also shares that, besides the new battery, CATL also unveiled a new brand called Naxtra for the company's Sodium-ion batteries. Sodium-ion batteries could help reduce the risk of a fire in EVs, some experts suggest.
Why It Matters: Last year, CATL, whose customers also include the likes of Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLKAF#OTC">VLKAF</a>) and Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), was seeking over <a href="https://www.benzinga.com/news/24/07/39745306/tesla-supplier-catl-seeks-1-5b-funding-to-expand-global-ev-battery-supply-chain">$1.5 billion in funding</a> to bolster its EV battery supply chain.&nbsp;
Elsewhere, fast-charging tech throughout the globe is experiencing rapid development. Recently, leading Chinese automaker BYD Co., Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDD#OTC">BYDD</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44630091/teslas-ev-crown-at-risk-as-byd-closes-in-with-breakthrough-charging-tech">unveiled its fast-charging technology</a>, which could provide approximately 250 miles of range through a 5-minute charge.
In contrast, Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44245123/teslas-charging-empire-faces-headwinds-as-ev-market-stumbles">superchargers provide 170 miles</a> of range on a 10-minute charge, significantly lower than BYD's tech.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link</a>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44892799/teslas-india-play-deepens-as-elon-musks-ev-giant-explores-alternate-semiconductor-supply-chains-amid-us-china-trade-war">Tesla&#8217;s India Play Deepens As Elon Musk&#8217;s EV Giant Explores Alternate Semiconductor Supply Chains Amid US-China Trade War</a></li>
</ul>
Image Via Shutterstock

Comments

HOOKIPA Pharma

HOOKIPA Pharma (HOOK) Opciones

HOOKIPA Pharma (NASDAQ:HOOK) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL